Landiolol in the treatment of the intraoperative supraventricular tachycardia: a multi-center, randomized, double-blind, placebo-controlled study

Efficacy and safety of landiolol in the treatment of the intraoperative supraventricular tachycardia

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12003021

Enrollment

Unknown

Registered

2012-11-26

Start date

2012-06-04

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intraoperative supraventricular tachycardia

Interventions

control:Placebo

experiment:Landiolol

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 70 years old; 2. The duration of intraoperative supraventricular tachycardia > 100 beats/min, except for the tachycardia resulted from specific causes such as hypovolemia, light anesthesia; 3. The sinus tachycardia lasted more than three minutes, or the supraventricular tachycardia outside of the sinus tachycardia lasted more than 1 min.

Exclusion criteria

Exclusion criteria: /

Design outcomes

Primary

Measure	Time frame
midway change rate;	—

Secondary

Measure	Time frame
HR, BP, RPP and ECG;the improvement of supraventricular tachycardia;the required time when a decrease of the heart rate ;the required time when the heart rate reached <100;	—

Countries

China

Contacts

Public ContactWang Xiangrui

wangxiangrui021@163.com+86 021-33070834

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 19, 2026